HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Outset Medical (OM) Shareholders with Losses to Contact its Attorneys, Firm Investigating Possible Securities Law Violations
As a result, Outset suspended 2022 and long-term financial guidance.
- As a result, Outset suspended 2022 and long-term financial guidance.
- In late July 2022, Outset disclosed the FDA cleared the 510(k) application of Tablo for patient use in the home.
- More recently, on Oct. 12, 2023, Outset Medical reported disappointing preliminary Q3 2023 revenues and slashed its FY 2023 revenue guidance.
- “We’re focused on investors’ losses and investigating whether Outset may have misled investors about Tablo’s near-term prospects,” said Reed Kathrein, the Hagens Berman partner leading the investigation.